Atrial Septal Defect Market Report 2026

Atrial Septal Defect Market Overview

• Atrial Septal Defect market size has reached to $4.46 billion in 2025 • Expected to grow to $6.26 billion in 2030 at a compound annual growth rate (CAGR) of 6.8% • Growth Driver: Growing Prevalence of Congenital Heart Defects (CHD) Drive Atrial Septal Defect Market Expansion • Market Trend: Advancements In Occluders For Arterial Septal Defect Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Atrial Septal Defect Market?

An atrial septal defect (ASD) refers to a congenital heart defect characterized by an abnormal opening in the septum, the wall separating the heart's two upper chambers (atria). This opening allows oxygen-rich blood from the left atrium to mix with oxygen-poor blood in the right atrium, which can lead to increased blood flow to the lungs and over time cause complications like pulmonary hypertension and heart failure. The main treatment procedures for arterial septal defect are surgical closure, transcatheter closer, hybrid procedures, and medication therapy. Surgical closure refers to a procedure where an abnormal opening or defect in the body, such as in the heart, is repaired or sealed through surgical intervention. Diagnostic methods encompass chest x-rays, electrocardiograms, cardiac catheterization, transesophageal echocardiography, and pulse oximetry, facilitated by medical devices and pharmaceutical products. These diagnostics serve pediatric and adult patients across various end-user settings, including hospitals, ambulatory surgical centers, cardiac clinics, and others.

What Is The Atrial Septal Defect Market Growth Forecast?

The atrial septal defect market size is expected to see strong growth in the next few years. It will grow to $6.26 billion in 2030 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to increasing adoption of hybrid closure techniques, rising focus on early intervention in adults, expansion of minimally invasive cardiac surgery capabilities, growing innovation in occluder device design, increasing demand for long-term follow-up care solutions. Major trends in the forecast period include increasing adoption of transcatheter closure devices, rising preference for minimally invasive repair procedures, growing use of advanced cardiac imaging techniques, expansion of pediatric and adult asd screening programs, enhanced focus on long-term patient outcomes.

Global Atrial Septal Defect Market Segmentation

1) By Treatment Procedure: Surgical Closure, Transcatheter Closure, Hybrid Procedures, Medication Therapy 2) By Diagnosis: Chest X-Ray, Electrocardiogram, Cardiac Catheterization, Transesophageal Echocardiography, Pulse Oximetry 3) By Product Type: Medical Devices, Pharmaceutical Products 4) By Age Group: Pediatric, Adult 5) By End-User: Hospitals, Ambulatory Surgical Centers, Cardiac Clinics, Other End-Users Subsegments: 1) By Surgical Closure: Open Heart Surgery (Traditional Surgical Closure), Minimally Invasive Surgical Closure, Patches (Pericardial, Synthetic) For Asd Closure 2) By Transcatheter Closure: Device-Based Closure (Amplatzer Septal Occluder), Transcatheter Plug Closure Techniques, Catheter-Based Asd Repair For Adult And Pediatric Patients 3) By Hybrid Procedures: Combination Of Surgical And Transcatheter Techniques, Minimally Invasive Hybrid Procedures, Hybrid Closure For Complex Or Large Asds 4) By Medication Therapy: Anticoagulant Therapy (To Prevent Stroke), Diuretics (For Managing Symptoms), Antihypertensive Drugs (For Managing Associated Conditions), Off-Label Use Of Other Medications

What Is The Driver Of The Atrial Septal Defect Market?

The prevalence of congenital heart defects (CHD) is expected to propel the growth of the atrial septal defect market going forward. Congenital heart defects refer to structural abnormalities in the heart present at birth. The increasing prevalence of congenital heart defects refers to the growing number of individuals diagnosed with structural heart abnormalities present from birth. Atrial septal defect treatment helps manage congenital heart defects by correcting abnormal blood flow between the heart's chambers, improving overall heart function, and reducing associated complications. For instance, in September 2025, according to the British Heart Foundation, a UK-based non-profit organization, there are 2.3 million people in the UK living with congenital heart disease. Further, congenital heart disease defects are diagnosed in at least 1 in 150 births that's an average of 13 babies each day in the UK with more diagnoses later in life. Estimates suggest as many as 1-2 percent of the population may be affected. Therefore, the prevalence of congenital heart defects will drive the atrial septal defect industry.

Key Players In The Global Atrial Septal Defect Market

Major companies operating in the atrial septal defect market are Abbott Laboratories, Medtronic plc, Boston Scientific Corporation, Edwards Lifesciences Corporation, W. L. Gore & Associates Inc., Cook Medical, Lepu Medical Technology Co. Ltd., MicroPort Scientific Corporation, Lifetech Scientific Corporation, Venus Medtech Hangzhou Inc, Occlutech Holding AG, Osypka AG, Cardia Inc, Gore Medical, Pfm Medical AG, Balton Sp. z o.o., Meril Life Sciences, TTK Healthcare, Braile Biomedica, Shanghai Shape Memory Alloy

Global Atrial Septal Defect Market Trends and Insights

Major companies operating in the arterial septal defect market are developing advanced devices and seeking approval to increase their availability and uses. Device approval refers to obtaining official authorization or certification for a device, typically from a regulatory body or relevant authority, before it can be legally manufactured, sold, or used in a specific market or for a particular purpose. For instance, in March 2024, Occlutech GmbH, a Sweden-based specialist provider of minimally invasive cardiac devices, announced that the United States Food and Drug Administration (FDA) had approved the Occlutech ASD Occluder and Occlutech Pistol Pusher for treating atrial septal defects (ASD). This approval marks a significant milestone for the company, which has been working to advance healthcare globally. The Occlutech ASD Occluder is designed to be a lifelong solution for patients with echocardiography-confirmed defects. It is a self-expanding nitinol device that includes two flexible discs attached to both sides of the patient's atrial septum using the Occlutech Pistol Pusher. With this approval, Occlutech will begin commercialization in the US through an exclusive partnership with B. Braun Interventional Systems.

What Are Latest Mergers And Acquisitions In The Atrial Septal Defect Market?

In August 2024, Occlutech, a Switzerland-based provider of minimally invasive structural heart devices, in partnership with B.  Braun Interventional Systems, to commercial implantation of the Occlutech ASD Occluder in leading U.S. centers. Through this collaboration, the companies aim to provide an effective, minimally invasive solution for closing atrial septal defects, leveraging Occlutech’s strong clinical data and B. Braun’s U.S. commercialization infrastructure. This partnership underscores the ASD device market’s push toward regulatory-driven commercial expansion and broader patient access. B.  Braun Interventional Systems, a U.S.-based provider of interventional cardiovascular technologies.

Regional Outlook

North America was the largest region in the atrial septal defect market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Atrial Septal Defect Market?

The atrial septal defect (ASD) market consists of revenues earned by entities by provide services such as diagnosis and monitoring, medication management, and genetic counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The atrial septal defect (ASD) market also includes sales of septal occluder devices, cardiac MRI systems, and anticoagulant medications. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Atrial Septal Defect Market Report 2026?

The atrial septal defect market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the atrial septal defect industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.